Biomarker matched biologic use in patients with metastatic colorectal cancer (mCRC).
40 Background: The use of biologic therapy for patients with mCRC is incompletely characterized. We evaluated receipt of biomarker matched guideline concordant treatment with VEGF inhibitors (VEGFi), EGFR antibodies (EGFRa), and immune checkpoint inhibitors (ICI), assessing treatment by sociodemographic, clinic...